16
May
2017
Biotech People Care, But How Can the Industry Make a Difference?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
May
2017
Palpitations in PD-1/PD-L1 Land, a Mystery ALS Drug Approval, And a CAR-T Scare
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
May
2017
Seattle Biotech: See You at the TR 2nd Anniversary Party Tuesday at Adaptive
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
May
2017
House Passes Trumpcare, Alzheimer’s Drug Shenanigans, & An IPO Flurry
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
May
2017
Who’s Doing What in Long-Read and Linked-Read DNA Sequencing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Apr
2017
Biotech Execs Going to White House, NASH Buzz, & Zuckerberg Bankrolls Preprint Movement
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Apr
2017
David Baltimore on What it Takes to Create the Future
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Apr
2017
Verily, Verily Everywhere, Tesaro’s Cheaper PARP (Not Really), and a Juno Exec Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Apr
2017
Photos from the TR Anniversary Party and Boston Marathon
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Apr
2017
SEC Busts Paid Stock Pumpers, Neurocrine Scores FDA OK, BMS Unloads Two Assets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Apr
2017
Boston Biotech: See You At The TR Anniversary Party Thursday Afternoon
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Apr
2017
Gottlieb Nails Senate Hearing, 23andMe Back in FDA’s Good Grace, and AACR Reflections
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Apr
2017
Allen’s $100M Cell Biology Resource a Cool Idea With a Long Way to Go, Scientists Say
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Apr
2017
Six Clues That Show When an Academic Institution Is Serious About Entrepreneurship
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Mar
2017
FDA Commish Scrutiny, and a String of Big Approvals for Regeneron, Tesaro & Genentech
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Mar
2017
Third Rock’s Tango Gets $55M for CRISPR-Enabled Synthetic Lethal Cancer Combos
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Mar
2017
Don’t Miss the TR Anniversary Parties in Boston and Seattle
Ferris Bueller once said: “Life moves pretty fast. If you don’t stop and look around once in a while, you could miss it.” Timmerman Report started two years ago. It’s time to thank subscribers, and throw a couple free community parties – one in the East, one in the West. The Boston party will be on Apr. 13, and Seattle’s... Read More
24
Mar
2017
Amgen’s PCSK9 Mixed Bag, Regeneron & GSK’s Genomics Bet, and Healthcare Vote Stalls
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Mar
2017
The Opioid Crisis Needs Biotech. Nektar Drug Is a Half-Step
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Mar
2017
White House Wants to Gut NIH, Allergan’s CRISPR Foray, & New VCs Sprout Up
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.